Interestingly, in our study, we confirmed these findings in a well-selected naive to treatment Abneg RA patient cohort in which Abneg RA patients with high likelihood chance of DAS remission achievement after DMARD treatment were more likely characterized, at baseline, by IHC score for sublining CD68+ cells < 2.5 compared to Abneg RA patients not achieving DAS remission after DMARD treatment. This evidence concerns the gene CD68 and rheumatoid arthritis.